Literature DB >> 20375551

Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor.

Sergey S Seregin1, Zachary C Hartman, Daniel M Appledorn, Sarah Godbehere, Haixiang Jiang, Michael M Frank, Andrea Amalfitano.   

Abstract

Adenovirus (Ad) vectors are currently the most commonly utilized gene transfer vectors in humans worldwide. Unfortunately, upon contact with the circulatory system, Ads induce several, innate, complement-dependent toxicities that limit the full potential for Ad-based gene transfer applications. Therefore, we have constructed several novel Ad5-based vectors, 'capsid-displaying' as fiber or pIX fusion proteins, a complement-regulatory peptide (COMPinh). These novel Ads dramatically minimize Ad-dependent activation of the human and non-human primate complement systems, as determined by several assays. In summary, our work has shown that a novel COMPinh-displaying Ad5 has the potential for broadening the safe use of Ad vectors in future human applications. (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375551      PMCID: PMC2895756          DOI: 10.1159/000284368

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  29 in total

Review 1.  The innate immune response to adenovirus vectors.

Authors:  Daniel A Muruve
Journal:  Hum Gene Ther       Date:  2004-12       Impact factor: 5.695

2.  Bypassing complement: evolutionary lessons and future implications.

Authors:  John P Atkinson; Michael M Frank
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

3.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

4.  Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.

Authors:  Anne Kiang; Zachary C Hartman; Ruth S Everett; Delila Serra; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Mol Ther       Date:  2006-06-02       Impact factor: 11.454

5.  Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent.

Authors:  D M Appledorn; A Kiang; A McBride; H Jiang; S Seregin; J M Scott; R Stringer; Y Kousa; M Hoban; M M Frank; A Amalfitano
Journal:  Gene Ther       Date:  2008-02-21       Impact factor: 5.250

6.  Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy.

Authors:  Nicola Brunetti-Pierri; Gary E Stapleton; Donna J Palmer; Yu Zuo; Viraj P Mane; Milton J Finegold; Arthur L Beaudet; Michelle M Leland; Charles E Mullins; Philip Ng
Journal:  Mol Ther       Date:  2007-02-06       Impact factor: 11.454

Review 7.  Therapeutic inhibition of the complement system.

Authors:  S C Makrides
Journal:  Pharmacol Rev       Date:  1998-03       Impact factor: 25.468

8.  Human complement regulatory proteins protect swine lungs from xenogeneic injury.

Authors:  M Yeatman; C W Daggett; C L Lau; G W Byrne; J S Logan; J L Platt; R D Davis
Journal:  Ann Thorac Surg       Date:  1999-03       Impact factor: 4.330

9.  C5a and Fcgamma receptors: a mutual admiration society.

Authors:  John P Atkinson
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

10.  Design and NMR characterization of active analogues of compstatin containing non-natural amino acids.

Authors:  Buddhadeb Mallik; Madan Katragadda; Lynn A Spruce; Caterina Carafides; Christos G Tsokos; Dimitrios Morikis; John D Lambris
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

View more
  8 in total

1.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

2.  TUNABLE COMPLEMENT ACTIVATION BY PARTICLES WITH VARIABLE SIZE AND Fc DENSITY.

Authors:  Patricia M Pacheco; Benjamin LE; David White; Todd Sulchek
Journal:  Nano Life       Date:  2013-06

3.  Use of DAF-displaying adenovirus vectors reduces induction of transgene- and vector-specific adaptive immune responses in mice.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Jennifer Zehnder; Tyler Voss; Sarah Godbehere; Andrea Amalfitano
Journal:  Hum Gene Ther       Date:  2011-04-18       Impact factor: 5.695

4.  Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX.

Authors:  Kathy L Poulin; Robert M Lanthier; Adam C Smith; Carin Christou; Milagros Risco Quiroz; Karen L Powell; Ryan W O'Meara; Rashmi Kothary; Ian A Lorimer; Robin J Parks
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

Review 5.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

6.  Improving adenovirus based gene transfer: strategies to accomplish immune evasion.

Authors:  Sergey S Seregin; Andrea Amalfitano
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

7.  Using multivalent adenoviral vectors for HIV vaccination.

Authors:  Linlin Gu; Zan C Li; Alexandre Krendelchtchikov; Valentina Krendelchtchikova; Hongju Wu; Qiana L Matthews
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

8.  Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm.

Authors:  Yasser Ali Aldhamen; Sergey S Seregin; Andrea Amalfitano
Journal:  Front Immunol       Date:  2011-09-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.